Who Can Get Mounjaro on the NHS — and What Happens If You Don't Qualify

What are the current NHS criteria for getting Mounjaro?

NICE published its recommendation for tirzepatide (Mounjaro) in December 2024, and NHS England has since been implementing it in waves. As of June 2025, the first cohort of eligible patients is adults with a BMI of 40 or above who also have four or more of the following five conditions: type 2 diabetes, high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, and cardiovascular disease.

That is a narrow starting group by design. NHS England is being deliberate about capacity and supply while demand is high. If you want to understand who can have Mounjaro on the NHS in detail, the criteria are more specific than most people expect, and meeting one or two of those conditions, or having a BMI of 38, does not currently open the door, no matter how much clinical sense it might make in an individual case.

There is one important adjustment worth knowing about. For people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI threshold throughout the rollout is set 2.5 kg/m² lower, in line with UK guidance on the health risks associated with lower BMI in these populations. So the current threshold for those groups is effectively 37.5 rather than 40, with the same four-condition requirement. You can review the full criteria directly on the NICE tirzepatide appraisal (TA1026).

It is also worth checking with your GP practice directly, participating in the new prescribing arrangement is optional for GP surgeries, so even where you qualify on paper, your practice may not yet be set up to prescribe it.

How is NHS access to Mounjaro going to change over time?

The rollout is designed to expand in steps. The second cohort, covering people with a BMI of 35–39.9 and four or more of the same five qualifying conditions, became available from around June 2026. A further expansion to people with a BMI of 40 or above and three or more conditions is expected from around March 2027.

Each phase depends on NHS capacity, supply chain stability and what ICBs (Integrated Care Boards) can support locally. Dates are indicative rather than guaranteed, and availability will vary across England. Scotland, Wales and Northern Ireland are running separate commissioning processes, so the timeline for getting Mounjaro on the NHS looks different depending on where you live.

One practical habit worth building now: keep a record of any diagnosed conditions with the date of diagnosis, your GP can confirm what is on your Summary Care Record. If you are approaching the cohort criteria, having that documentation ready makes any future conversation with your practice much smoother. It takes less than a minute to ask your GP surgery to print a conditions summary at your next appointment.

Every NHS patient must also take part in wrap-around diet and activity support as a condition of treatment. Qualification on BMI and comorbidity alone is not a guarantee; your GP or specialist team will consider the full picture. More detail on the NHS route for Mounjaro is worth reading before your GP appointment.

What if you don't qualify for Mounjaro on the NHS right now?

The licensed eligibility criteria for private prescription sit lower than the current NHS thresholds. Under the Mounjaro SmPC, adults with a BMI of 30 or above (or a BMI of 27 or above with at least one weight-related condition) may be considered for treatment through a private prescriber, subject to full clinical assessment.

That means many people who do not yet qualify under the NHS phased rollout may still be eligible for a private prescription. A private route does not involve a waiting list or a referral. It does involve a real clinical review: identity verification, weight confirmation, a review of your health history, and a prescriber making a professional judgement about whether treatment is appropriate for you. For more on who meets the private eligibility criteria for Mounjaro, that page covers the full picture.

Understanding the cost of Mounjaro privately is a fair question at this point, and the answer is more nuanced than a headline price suggests. For people who can't access NHS treatment, private prescription is the only lawful route, and the clinical assessment that comes with it is not a formality. It exists to keep you safe.

Is the NHS offering Mounjaro or Wegovy, and does the difference matter?

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both licensed for weight management in the UK, but they are different medicines working through different mechanisms. Mounjaro activates two receptors (GIP and GLP-1) while Wegovy targets GLP-1 alone. Clinical trial evidence, including the SURMOUNT-5 head-to-head study published in the New England Journal of Medicine in 2025, showed tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks.

The NHS currently has separate pathways for each. Wegovy is available through specialist weight management services under NICE guidance TA875, which carries its own eligibility requirements including a BMI of 35 or above, at least one comorbidity, and treatment within a specialist service for a maximum of two years. Mounjaro on the NHS follows the TA1026 pathway described above.

Which medicine is the better fit for you is a clinical question, not a comparison article. If you're exploring your options, our treatment overview page gives a factual summary of both, and how to access Mounjaro through the NHS walks through the practical steps for people who do qualify. For those who don't, speaking to a prescriber privately is the next step, and our prescribers at nume are available the same day, with no waiting list involved.

If you'd like a clinical team to assess your suitability for private treatment, you're welcome to speak to our prescribers. There's no charge for the consultation.